3.5 Publications

September 21, 2021

Deep Multimodal Fusion for the Discovery of Prognostic Biomarkers Integrating Radiology, Histology, and Molecular Information

Medical Image Computing and Computer Assisted Intervention 2021, Tempus-authored — Clinical decision-making in oncology involves multimodal data such as radiology scans, molecular profiling, histopathology slides, and clinical factors. Despite the importance of these modalities individually, no deep learning framework to date has combined them all to predict patient prognosis. Here, we predic...

September 9, 2021

Multi-Platform Classification of IDH-Wild-Type Glioblastoma Based on ERK/MAPK Pathway: Diagnostic, Prognostic and Therapeutic Implications

Cancers, Tempus-acknowledged — Glioblastoma is the most aggressive and frequent glioma in the adult population. Because current therapy regimens confer only minimal survival benefit, molecular subgrouping to stratify patient prognosis and therapy design is warranted. This study presents a multi-platform classification of glioblastoma by analyzing a large, ethnicity-inclusive...

September 8, 2021

Ancestry Inference From Targeted NGS Tests to Enable Precision Medicine and Improve Racial/Ethnic Representation in Clinical Trials

AGBT Precision Health Meeting, Tempus-authored — There are well-established racial and ethnic disparities in cancer incidence and outcomes, in part due to structural, socioeconomic, environmental, and behavioral factors. Some of these differences can be attributed to biological factors, such as cancer mutation frequencies that vary by ancestry. It is well known that diversi...

August 24, 2021

The Friends of Cancer Research Real World Data (RWD) Pilot 2.0 Collaboration: Implementation of Standardized Methodological Approaches for Evaluation of Oncology RWD

ISPE Annual Meeting 2021, Tempus-authored — Background: Real-world evidence (RWE) can reflect more broad and diverse patient populations than traditional clinical trials but challenges remain in using real-world data (RWD) to support clinical research, drug development, and regulatory decision-making. Operationalizing standardized variable definitions and implementing consistent statistical methods are e...

August 16, 2021

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance

Biomedicines, Tempus-acknowledged — The development of patient-derived tumor organoids (TOs) from an epithelial ovarian cancer tumor obtained at the time of primary or interval debulking surgery has the potential to play an important role in precision medicine. Here, we utilized TOs to test front-line chemotherapy sensitivity and to investigate genomic driv...

August 4, 2021

Germline ATM Mutation and Somatic PIK3CA and BCOR Mutations Found in an Infant With Aggressive Orbital Embryonal Rhabdomyosarcoma

American Journal of Ophthalmology Case Reports, Tempus-acknowledged — Purpose To report a case of aggressive infantile orbital embryonal rhabdomyosarcoma harboring germline ATM mutation and 2 somatic mutations as revealed by next-generation sequencing and the potential application for personalized therapy. Observations A 7-month-old male developed a rapidly progressive left proptosis over 6 weeks due to a l...

July 27, 2021

A Pan-Cancer Organoid Platform for Precision Medicine

Cell Reports, Tempus-authored — Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of scalable and reproducible methods to develop and profile these models. We describe a r...

July 5, 2021

Somatic Tumor Profile Analysis in a Patient with Germline PMS2 Mutation and Synchronous Ovarian and Uterine Carcinomas

Journal of Personalized Medicine, Tempus-authored — Lynch syndrome patients with synchronous endometrial and ovarian cancer (SEOC) are rare. When these cases occur, they are most often endometrioid histology and early grade. Early-grade tumors are not often sent for somatic tumor profiling. We present a 39 year old SEOC patient with...

July 2, 2021

Validation of a Liquid Biopsy Assay With Molecular and Clinical Profiling of Circulating Tumor DNA

npj Precision Oncology, Tempus-authored — Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-invasive approach to identify biomarkers, detect resistance mutations, monitor disease burden, and identify early recurrence. The Tempus xF liquid biopsy assay is a 105-gene, hybrid-capture, next-generation sequencing (NGS) assay that d...

July 2, 2021

Deep Orthogonal Fusion: Multimodal Prognostic Biomarker Discovery Integrating Radiology, Pathology, Genomic, and Clinical Data

arXiv, Tempus-authored — Clinical decision-making in oncology involves multimodal data such as radiology scans, molecular profiling, histopathology slides, and clinical factors. Despite the importance of these modalities individually, no deep learning framework to date has combined them all to predict patient prognosis. Here, we predict the overall survival (OS...

Show More